Diagnos (FRA:4D4A) Moat Score: 3/10 (As of Jul. 19, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:4D4A Diagnos Inc FRA:4D4A
23 GF Score
Price €0.14
! 5 Warning Signs
View Full Analysis

What is Diagnos Moat Score?

Diagnos FRA:4D4A -8.05% 23 Moat Score is 3 as of Jul. 19, 2026. GuruFocus rates FRA:4D4A with a GF Score™ of 23/100. The stock has 5 warning signs investors should review. Among 673 Healthcare Providers & Services companies, Diagnos ranks better than 84.4% on this metric.

Diagnos has the Moat Score of 3, which implies that the company might have No Moat - Very weak/transient advantages.

Diagnos has No Moat: Diagnos Inc has a weak moat with some intellectual property in medical diagnostics, but lacks significant market share, brand strength, or regulatory barriers to protect its position against larger competitors.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Diagnos might have No Moat - Very weak/transient advantages.

Diagnos  (FRA:4D4A) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Diagnos Moat Score Related Terms

FRA:4D4A vs VEEV, BTSG, TEM: Moat Score Comparison

For the Health Information Services subindustry, Diagnos's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Diagnos Moat Score vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Diagnos's Moat Score distribution charts can be found below:

* The bar in red indicates where Diagnos's Moat Score falls into.


FRA:4D4A
23GF Score
Diagnos Inc FRA:4D4A
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 3 mean?
Diagnos (FRA:4D4A) has a Moat Score of 3 as of Jul. 19, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Diagnos ranks #105 out of 673 companies in the Healthcare Providers & Services industry, placing it in the top 15.6%.
Is Diagnos' Moat Score too high?
Diagnos' current Moat Score is 3. Based on the distribution chart, Diagnos ranks #105 out of 673 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Diagnos has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Diagnos' Moat Score compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Diagnos ranks #105 out of 673 companies for Moat Score. This places Diagnos in the top 16% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Healthcare Providers & Services company?
A good Moat Score depends on the Healthcare Providers & Services industry context. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. Diagnos's current Moat Score is 3. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Diagnos stock overvalued right now?
Diagnos (FRA:4D4A) has a current Moat Score of 3. The current Moat Score is 3. Diagnos' overall GF Score™ is 23/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Diagnos (FRA:4D4A), the current Moat Score is 3 as of Jul. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Diagnos Business Description

Other Exchanges DGNOF:USAADK:Canada
Address 7005 Taschereau Boulevard, Suite 265, Brossard, Longueuil, QC, CAN, J4Z 1A7
Diagnos Inc is engaged in the provision of software-based interpretation services to assist health specialists in the detection of diabetic retinopathy. The company provides image analysis services through CARA (Computer Assisted Retinal Analysis). It operates in a single business segment of Healthcare services. The company has a business presence in Canada, United States of America, Mexico, Chile and others. The company's key revenue is derived from Canada.
23GF Score

Get the complete analysis for FRA:4D4A

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.14
Price